Vital Therapies (VTL) – FDA
-
Vital Therapies (VTL) Says Topline Results of VTL-308 Fail to Achieve Primary and Secondary Endpoints of Improvement in Survival
-
Vital Therapies (VTL) Achieves Enrollment Target of 150 Subjects for VTL-308 Phase 3 Trial
-
-
-
-
-
-
-
-
-
Back to VTL Stock Lookup